DSP-2230
In-game article clicks load inline without leaving the challenge.
DSP-2230 is a selective small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain. As of June 2014, it is in phase I/phase II clinical trials.
See also
External links
- . AdisInsight. Springer Nature Switzerland AG.